Skip Navigation

Press Releases

Displaying 1 to 14 of 14 files.

2009 Press Releases

  Acura Pharmaceuticals Reports Third Quarter 2009 Financial Results (32.6 KiB) - added October 26, 2009

  Acura Pharmaceuticals And King Pharmaceuticals Provide Update On Acurox® NDA (40.7 KiB) - added September 3, 2009

  Acura Pharmaceuticals Submits Acurox® Briefing Package To FDA (26.3 KiB) - added August 6, 2009

  Acura Pharmaceuticals Reports Second Quarter 2009 Financial Results (32.6 KiB) - added July 30, 2009

  Acura and King Receive FDA Complete Response Letter Regarding Acurox® (115.0 KiB) - added July 2, 2009

  Acura Pharmaceuticals Receives Preliminary Review Letter From FDA Regarding Acurox® (24.8 KiB) - added June 23, 2009

  Acura Pharmaceuticals Reports First Quarter 2009 Financial Results (29.8 KiB) - added May 1, 2009

  Excess Oral Doses Of Acurox® Tablets Are Disliked By Subjects With A History Of Opioid Abuse (50.6 KiB) - added May 1, 2009

  Acura Pharmaceuticals, Inc. Names Garth Boehm, Ph.D. VP of Modified Release Dosage Form Development (24.3 KiB) - added March 26, 2009

  Acura Pharmaceuticals To Present At Cowen And Company Health Care Conference (19.9 KiB) - added March 11, 2009

  Acurox® Tablets New Drug Application Accepted For Filing With A Priority Review Classification (44.2 KiB) - added March 3, 2009

  Acura Pharmaceuticals Reports Year-End and Fourth Quarter 2008 Financial Results (35.2 KiB) - added March 2, 2009

  Acura Pharmaceuticals, Inc. Names Albert W. Brzeczko, Ph.D. VP, Technical Affairs (20.0 KiB) - added February 9, 2009

  New Drug Application Submitted for Acurox® Tablets (98.7 KiB) - added January 2, 2009

Displaying 1 to 13 of 13 files.

2008 Press Releases

  King Pharmaceuticals Exercises Option To License Fourth Opioid Product From Acura Pharmaceuticals (40.0 KiB) - added December 24, 2008

  Acura Pharmaceuticals, Inc. Reports Third Quarter 2008 Financial Results (31.8 KiB) - added October 27, 2008

  Acura Pharmaceuticals And King Pharmaceuticals Announce Positive Top Line Results Of Key Clinical Study Assessing Abuse Liability (43.6 KiB) - added October 13, 2008

  Acura Pharmaceuticals, Inc. To Present At Natixis Bleichroeder Hidden Gems Conference (19.9 KiB) - added October 10, 2008

  Acura Pharmaceuticals, Inc. Announces Return Of President And CEO From Medical Leave (19.7 KiB) - added September 2, 2008

  Acura Pharmaceuticals, Inc. Reports Second Quarter 2008 Financial Results (31.3 KiB) - added July 30, 2008

  Acura Pharmaceuticals, Inc. Announces Action Regarding Notice Of Allowance Received For Second Aversion® Technology Patent (26.6 KiB) - added July 21, 2008

  Acura Pharmaceuticals, Inc. Added To The Russell 3000® Index And The Russell Microcap® Index (27.5 KiB) - added June 30, 2008

  Acura Pharmaceuticals, Inc. Receives $5.0 Million Milestone Payment (27.6 KiB) - added June 30, 2008

  Acurox™ Tablets Meet Primary Endpoint In Pivotal Phase III Study (51.3 KiB) - added June 17, 2008

  Acura Pharmaceuticals, Inc. Announces Notice Of Allowance For Second Aversion® Technology Patent (26.2 KiB) - added June 3, 2008

  Acura Pharmaceuticals, Inc. Announces Active IND For Second Opioid Analgesic Product Candidate Using Aversion® Technology (23.5 KiB) - added June 2, 2008

  King Pharmaceuticals Exercises Option To License Third Opioid Product Utilizing Acura's Aversion® Technology (42.0 KiB) - added May 27, 2008